Drug Trial Radar · NCT05636267
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
59
Actual
Start
Feb 10, 2023
Primary completion
Feb 24, 2025
Study completion Apr 15, 2025
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.
Conditions
- NSCLC
Interventions
AK119Drug
AK119 IV every 3 weeks.
AK112Drug
AK112 IV every 3 weeks.
PemetrexedDrug
Pemetrexed IV every 3 weeks.
CarboplatinDrug
Carboplatin IV every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with dose limiting toxicities (DLTs)Time frame: During the first 3 weeks
- Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug
- Objective response rate (ORR)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.